What Caffetin Menstrual Treats: Main Uses and Benefits

Caffetin Menstrual provides symptomatic support as a widely used NSAID, and is commonly used to provide supportive relief across several symptomatic domains, offering short-term symptomatic assistance when discomfort interferes with daily comfort. This medicine is relevant for easing various forms of discomfort and is used for managing fever.

It is primarily used for primary dysmenorrhea (painful menstrual cramps), and is also relevant for easing symptoms related to common aches, including tension headaches, muscle aches, and backaches. In these scenarios, the medication supports patients during episodes of heightened discomfort by easing the overall symptom load.

The medication is used across domains where additional symptomatic support is needed, addressing symptom clusters related to inflammatory or irritative states (like swelling and stiffness). It is also used for managing elevated body temperature (fever) often associated with temporary physiological imbalance. This helps provide supportive relief when a temporary physiological imbalance creates heightened systemic burden.

Quick Fact: Relief for Menstrual Cramps is provided by managing pain during phases when symptoms become more noticeable.

Regulatory References

1. NIH MedlinePlus overview of Ibuprofen

Caffetin Menstrual's eligibility profile, based on its active ingredient Ibuprofen (an NSAID), defines strict population boundaries and non-eligibility rules in regulatory documents.

---

Populations for whom use is allowed

Use is established for adults and adolescents aged 12 years and older who do not have documented contraindications.

---

Populations for whom use is contraindicated

• Patients with hypersensitivity to Ibuprofen, aspirin, or any other NSAID.
• Individuals with active peptic ulceration or a history of gastrointestinal bleeding or perforation.
• Patients with severe renal failure, severe hepatic failure, or severe heart failure (e.g., NYHA Class IV).
• Women who are in the last trimester of pregnancy (at or after 20 weeks of gestation).
• Patients immediately before or after Coronary Artery Bypass Graft (CABG) surgery.

---

Age- and Condition-Specific Eligibility Rules

• Children under 12 years: Use of the 200 mg tablet is not recommended or contraindicated.
• Elderly Patients: Classified as an increased risk population for serious gastrointestinal and cardiovascular events, requiring special caution.
• Pregnancy: Use in the first and second trimesters is not recommended or restricted. Use while breastfeeding is generally considered acceptable in minimal amounts, but use should be restricted to the lowest necessary dose and duration.

Interactions with Other Medicines and Products

The interaction profile for Caffetin Menstrual, which contains Ibuprofen, is defined by several mandatory restrictions and documented co-administration constraints as outlined in official government regulatory labeling. The highest level of restriction involves contraindicated combinations due to additive toxicity.

---

Official Interaction Statements

Classification	Interacting Substances/Agents	Documented Regulatory Outcome
Contraindicated	Other NSAIDs (including COX-2 inhibitors), Acetylsalicylic Acid (Aspirin) > 75 mg daily	Increased risk of serious adverse events, including gastrointestinal bleeding and ulceration.
Pharmacodynamic	Anticoagulants, Antiplatelet Agents, SSRI/SNRI antidepressants, Oral Corticosteroids	Additive risk of bleeding, especially from the gastrointestinal tract.
Efficacy Reduction	Antihypertensive Agents (ACE inhibitors, ARBs, Beta-Blockers), Diuretics	May reduce the therapeutic effect of co-administered medicine and may increase the risk of renal deterioration.
Exposure Alteration	Lithium, Methotrexate, Cardiac Glycosides	Reduced renal clearance, leading to increased plasma concentration and potential toxicity of the co-administered medicine.

---

Timing and Procedural Restrictions

Official labeling requires timing separation for co-administration with low-dose, non-enteric coated Aspirin: Ibuprofen must be administered at least 8 hours before or 30 minutes after the Aspirin dose to avoid documented interference with its antiplatelet effect. The medicine is also contraindicated for use in the setting of Coronary Artery Bypass Graft (CABG) surgery and during the third trimester of pregnancy. Co-consumption with Alcohol is documented to increase the risk of gastrointestinal bleeding.

The mechanism of Caffetin Menstrual, driven by Ibuprofen, is fundamentally based on the reversible, non-selective inhibition of the Cyclooxygenase (COX) enzyme family, specifically COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid into various prostaglandins and other prostanoids. By blocking the active site of COX, the drug functionally modifies this early molecular step, initiating a cascade that results in the suppression of prostaglandin synthesis.

The resulting decrease in prostaglandin availability modulates three key physiological processes: it alters the sensitization threshold of peripheral pain nerves (nociceptors), it modulates the elevated temperature set-point in the central nervous system (hypothalamus), and it decreases the incidence and magnitude of smooth muscle contractions in the uterus. This dampening of prostaglandin-driven processes results in an overall physiological shift across multiple relevant systems.

Caffetin Menstrual is formulated as the highly soluble lysinate salt, which promotes the rapid delivery and engagement of the COX enzyme targets, thereby accelerating the onset of the inhibitory cascade and the corresponding physiological modulation.

Caffetin Menstrual is administered via the oral route as a film-coated tablet intended for systemic use. The instructions dictate a structured approach to ensure the medicine is used strictly within the established limits.

The typical single dose for adults and adolescents aged 12 years and older is one or two tablets, corresponding to 200 mg to 400 mg of Ibuprofen. Dosing should be repeated only as needed, maintaining a frequency of every 4 to 6 hours, with a minimum interval of four hours between doses. The maximum amount permitted over a 24-hour period is 1200 mg for non-prescription use, a limit established across standard product labeling.

Administration should commence at the earliest sign of discomfort. The tablet must be swallowed whole with water. It is advised that the medicine may be taken with or after food to assist with gastrointestinal tolerability.

This medicine is intended for short-term use only. The overarching procedural instruction is to always employ the smallest effective dose for the shortest duration required to manage symptoms. Dose modifications, such as using the lowest possible dose, are generally advised for patients with impaired renal or hepatic function.

Caffetin Menstrual: Recent Clinical Evidence

Caffetin Menstrual is a non-prescription combination analgesic formulated to manage primary dysmenorrhea, commonly known as menstrual cramps. The product typically combines Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), with Caffeine.

Efficacy in Dysmenorrhea

Clinical research focuses on the components, primarily Ibuprofen, which acts by inhibiting the synthesis of prostaglandins. Prostaglandins are key compounds involved in initiating the painful contractions of the uterus during menstruation. Multiple large-scale reviews, including those from authoritative global bodies, consistently report that Ibuprofen is an effective first-line treatment for managing menstrual pain when used at recommended doses.

• Pain Reduction: Studies indicate that Ibuprofen significantly reduces pain intensity and the duration of pain compared to placebo in women experiencing primary dysmenorrhea.
• Caffeine's Role: Caffeine is included as an adjuvant, meaning it is intended to enhance the pain-relieving effects of the analgesic component. Evidence suggests that caffeine may increase the absorption rate of NSAIDs, potentially contributing to a faster onset of pain relief, and may also possess mild analgesic properties itself.

---

Safety and Tolerability

The safety profile is primarily driven by Ibuprofen. Short-term use of Ibuprofen at non-prescription doses for dysmenorrhea is generally well-tolerated. Common, short-term adverse effects observed in clinical trials are typically gastrointestinal in nature, such as dyspepsia or nausea. Due to the combination with caffeine, some users may experience effects like insomnia, nervousness, or increased heart rate. Individuals with specific medical conditions should consult a healthcare professional before use.

Key Studies & References Clinical Practice Guideline for the Management of Acute Pain in the Adult

Common questions about Caffetin Menstrual (FAQ)

---

Q: Does Caffetin Menstrual contain caffeine or codeine?

A: Official composition documents state that the primary active substance is Ibuprofen. The product may be formulated with Caffeine as an adjuvant, which has been described as enhancing the analgesic effect. However, according to the official product information, it does not contain codeine.

Q: What is the difference between Ibuprofen and Ibuprofen lysinate, the ingredient in Caffetin Menstrual?

A: Ibuprofen lysinate is a salt form of Ibuprofen. Regulatory documents describe this formulation as promoting a faster dissolution and absorption rate compared to standard Ibuprofen preparations. Regulatory documents indicate that this chemical modification is associated with an accelerated onset of action.

Q: How long does it typically take for Caffetin Menstrual to start providing pain relief?

A: Clinical data and official information indicate that the onset of pain relief can occur. Due to the fast absorption of the lysinate salt formulation, the analgesic effect has been reported in clinical studies to begin within 15 to 30 minutes after administration.

Q: How long can the pain relief effects from Caffetin Menstrual be expected to last?

A: The duration of the analgesic effect can be inferred from the regulatory dosing guidelines. Official instructions indicate that the medicine may be repeated every 4 to 6 hours as needed to maintain relief.

Q: What is the main difference between Caffetin Menstrual and regular Ibuprofen tablets?

A: The primary difference lies in the formulation: Caffetin Menstrual uses Ibuprofen lysinate, a salt designed for faster absorption and a quicker onset of action. Furthermore, this product may also include Caffeine as an adjuvant, which is a component not found in single-ingredient Ibuprofen preparations.

Q: Is Caffetin Menstrual suitable for individuals with asthma or aspirin sensitivity?

A: The medicine is contraindicated for patients who have a history of hypersensitivity or allergic reactions to Ibuprofen, aspirin, or any other NSAID. Regulatory warnings also advise caution or contraindicate use in patients with a history of asthma or bronchospasm.

Q: Does taking Caffetin Menstrual on an empty stomach affect how quickly it works?

A: Taking the tablet after food is advised in regulatory documents to assist with gastrointestinal tolerability and reduce the risk of stomach upset. While taking it without food may lead to a slightly faster absorption rate, this should be balanced against the increased risk of gastrointestinal adverse effects.

Q: What is the regulatory status of Caffetin Menstrual (e.g., OTC or prescription-only)?

A: This product is generally classified as an Over-the-Counter (OTC) medicine when used within the established limits for non-prescription sales. The maximum dose is set at 1200 mg per 24 hours for use without a prescription.

Q: Are there any warnings about using Caffetin Menstrual before or after a minor surgery?

A: Official regulatory documents explicitly contraindicate the use of the medicine immediately before or after Coronary Artery Bypass Graft (CABG) surgery. Restrictions or specific warnings for minor surgeries are not typically specified in the official labeling.

Q: What is the maximum number of days in a row that Caffetin Menstrual is intended to be used?

A: Official labeling advises that use be limited to a maximum of 3 consecutive days for pain relief, unless otherwise directed by a healthcare professional.

Q: Can Caffetin Menstrual be taken by individuals with high blood pressure?

A: Official warnings describe a risk of fluid retention and advise caution for patients with uncontrolled hypertension (high blood pressure) or heart failure. The medicine is also documented to potentially reduce the efficacy of some medications used to treat high blood pressure.

Q: What information is available regarding the long-term safety of using Caffetin Menstrual monthly?

A: Regulatory information mandates that the medicine be used for the shortest duration necessary and at the lowest effective dose. The risks of serious gastrointestinal and cardiovascular events are officially associated with high doses and long-term continuous use, emphasizing that the product is intended for short-term, symptomatic relief.

Q: Can Caffetin Menstrual cause drowsiness or affect my ability to concentrate?

A: Official labeling lists some central nervous system effects, such as headache, dizziness, or fatigue, as possible uncommon side effects. If a user experiences these effects, regulatory warnings advise caution when performing activities that require concentration, such as driving or operating machinery.

Q: Does Caffetin Menstrual have any known interactions with hormonal birth control?

A: The official product information lists documented interactions with various therapeutic classes of medicines, such as anticoagulants and antihypertensives. Specific mandatory restrictions or warnings concerning common hormonal contraceptives are not typically listed in the interaction profile.

Q: Can Caffetin Menstrual affect fertility or is it safe for women who are trying to conceive?

A: Regulatory documents state that the use of Ibuprofen may impair female fertility by affecting ovulation. This effect is described as reversible upon cessation of the medicine.

Q: Is Caffetin Menstrual available in different tablet strengths or forms?

A: The product is most commonly described as a film-coated tablet containing 200 mg of Ibuprofen. While regulatory listings in some markets may include different strengths or package sizes, the 200 mg tablet is the widely recognized non-prescription form.

Storage and Disposal Requirements

The storage and disposal of Caffetin Menstrual film-coated tablets must strictly follow the conditions defined by regulatory labeling to maintain product quality and ensure safety.

Item	Regulatory Requirement
Storage Temperature	Store at a temperature below 25°C (Controlled Room Temperature).
Protection	Must be protected from light to prevent degradation.
Child Safety	Keep out of the reach of children to prevent accidental ingestion.
Stability	Do not use the product after the expiry date stated on the carton.
Disposal	Unused or expired product must be disposed of in accordance with local requirements (e.g., returned to a pharmacy) and not in wastewater or household trash.

These requirements ensure the medicine remains stable until its expiry date and is disposed of safely as pharmaceutical waste.